Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Guideline

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update

Sheldon W. Tobe, James A. Stone, Todd Anderson, Simon Bacon, Alice Y.Y. Cheng, Stella S. Daskalopoulou, Justin A. Ezekowitz, Jean C. Gregoire, Gord Gubitz, Rahul Jain, Karim Keshavjee, Patty Lindsay, Mary L’Abbe, David C.W. Lau, Lawrence A. Leiter, Eileen O’Meara, Glen J. Pearson, Doreen M. Rabi, Diana Sherifali, Peter Selby, Jack V. Tu, Sean Wharton, Kimberly M. Walker, Diane Hua-Stewart and Peter P. Liu
CMAJ October 09, 2018 190 (40) E1192-E1206; DOI: https://doi.org/10.1503/cmaj.180194
Sheldon W. Tobe
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James A. Stone
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd Anderson
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Bacon
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Y.Y. Cheng
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stella S. Daskalopoulou
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin A. Ezekowitz
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean C. Gregoire
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gord Gubitz
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rahul Jain
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karim Keshavjee
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patty Lindsay
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary L’Abbe
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C.W. Lau
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence A. Leiter
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eileen O’Meara
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glen J. Pearson
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doreen M. Rabi
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Sherifali
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Selby
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack V. Tu
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Wharton
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly M. Walker
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane Hua-Stewart
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter P. Liu
Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta.; Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que.; St. Michael’s Hospital (Cheng), University of Toronto, Toronto, Ont.; McGill University (Daskalopoulou), Montreal, Que.; Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta.; Institut de cardiologie de Montreal (Gregoire), Montreal, Que.; Universite de Montreal (Gubitz), Montreal, Que.; Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont.; Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont.; Department of Nutritional Sciences (L’Abbe), University of Toronto, Toronto, Ont.; Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Li Ka Shing Knowledge Institute (Leiter), St. Michael’s Hospital, University of Toronto, Toronto, Ont.; Heart and Stroke Foundation (Lindsay), Ottawa, Ont.; Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont.; Insitut de Cardiologie de Montreal (O’Meara), Universite de Montreal, Montreal, Que.; Division of Cardiology, Mazankowski Alberta Heart Institute; University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta.; Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta.; Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont.; School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont.; Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta.; Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont.; St. Joseph’s Health Care Centre (Walker), Toronto, Ont.; McMaster University (Wharton), Hamilton Ont.; York University (Wharton), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Tables

    • View popup
    Table 1:

    C-CHANGE guideline partners and methodology

    Guideline groupGrading system or methodology
    Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-Informed Tobacco Treatment1This independent expert body in guideline review conducted a review and identified 6 guidelines that met criteria for quality and applicability to local context. Summary statements were extracted and assigned a grade of recommendation and level of evidence by a second expert panel.2 The ADAPTE framework was used to guide the contextual adaptation (www.g-i-n.net/working-groups/adaptation/history); AGREE II was used to rate and select appropriate guidelines.
    Canadian Cardiovascular Society – guideline for the management of heart failure3GRADE
    Canadian Cardiovascular Society – guideline for the management of dyslipidemia4GRADE
    Canadian Association of Cardiovascular Prevention and RehabilitationHypertension Canada process (www.hypertension.ca)
    Canadian Society for Exercise Physiology5The Canadian Society for Exercise Physiology guideline steering committee used the AMSTAR tool (www.amstar.ca/docs/AMSTARguideline.pdf) to assess the methodological quality of the systematic reviews; conclusions from the reviews were assigned a level of evidence6–9 based on quality of the study, and level of evidence was used to develop appropriate wording for the guideline.
    Diabetes Canada10Diabetes Canada process (www.guidelines.diabetes.ca/)
    Hypertension Canada11Hypertension Canada process (www.hypertension.ca)
    Canadian Association of Bariatric Physicians and Surgeons/Obesity Canada12GRADE
    Heart and Stroke Foundation13GRADE
    • Note: AGREE II = Appraisal of Guidelines for Research & Evaluation II, AMSTAR = Assessment of Multiple Systematic Reviews, C-CHANGE = Canadian Cardiovascular Harmonized National Guidelines Endeavour, GRADE = the Grading of Recommendations, Assessment, Development and Evaluation framework.14

    • View popup
    Table 2:

    Body habitus: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline
    Heart failure
    We suggest daily morning weight should be monitored in patients with heart failure, with fluid retention or congestion that is not easily controlled with diuretics, or in patients with significant renal dysfunction.HF†
    • Note: C-CHANGE = Canadian Cardiovascular Harmonized National Guidelines Endeavour, HF = Canadian Cardiovascular Society – Heart Failure.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1 for a detailed discussion of the supporting evidence).

    • ↵† Based on consensus opinion.

    • View popup
    Table 3:

    Diet, and sodium and alcohol intake: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline (key supporting reference)
    All
    To prevent hypertension and reduce blood pressure in hypertensive adults, consider reducing sodium intake toward 2000 mg (5 g of salt or 87 mmol of sodium) per day.HC19
    We suggest that all individuals be encouraged to moderate energy (caloric) intake to achieve and maintain a healthy body weight and adopt a healthy dietary pattern to lower their risk of cardiovascular disease:
    • Mediterranean dietary pattern

    • Portfolio dietary pattern

    • DASH dietary pattern

    • Dietary patterns high in nuts (≥ 30 g/d)

    • Dietary patterns high in legumes (≥ 4 servings/wk)

    • Dietary patterns high in olive oil (≥ 60 mL/d)

    • Dietary patterns rich in fruits and vegetables (≥ 5 servings/d)

    • Dietary patterns high in total fibre (≥ 30 g/d); and whole grains (≥ 3 servings/d)

    • Low glycemic load or low glycemic index dietary patterns

    • Vegetarian dietary patterns

    CCS20
    Diabetes
    People with diabetes should be offered timely self-management education that is tailored to enhancing self-care practices and behaviours.DC21
    Overweight or obesity
    A dietary plan for improving health for adults with obesity should be part of a weight-management strategy.Obesity22
    A comprehensive healthy lifestyle intervention is recommended for people with overweight and obesity.Obesity23
    • Note: C-CHANGE = Canadian Cardiovascular Harmonized National Guidelines Endeavour, CCS = Canadian Cardiovascular Society – Dyslipidemia, DASH = Dietary Approaches to Stopping Hypertension, DC = Diabetes Canada (formerly Canadian Diabetes Association), HC = Hypertension Canada, Obesity = Obesity Canada.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10-1503/cmaj.180194/-/DC1, for a detailed discussion of the supporting evidence. Key references are indicated in this table.)

    • View popup
    Table 4:

    Risk factor screening: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline (key supporting reference)
    All
    Screening for diabetes using FPG and/or A1C should be performed every 3 yr in individuals aged ≥ 40 yr or at high risk, using a risk calculator. Earlier testing and more frequent follow-up (every 6 to 12 mo) with either FPG and/or A1C or 2hPG in a 75 g OGTT should be considered in those at very high risk, using a risk calculator, or in people with additional risk factors for type 2 diabetes. These risk factors include:
    • Age ≥ 40 yr

    • First-degree relative with type 2 diabetes

    • Member of high-risk population (e.g., African, Arab, Asian, Hispanic, Indigenous or South Asian descent; low socioeconomic status)

    • History of prediabetes (lGT, lFG or A1C 6.0%–6.4%)

    • History of GDM

    • History of delivery of a macrosomic infant

    • Presence of end organ damage associated with diabetes:

      • Microvascular (retinopathy, neuropathy, nephropathy)

      • Cardiovascular (coronary, cerebrovascular, peripheral)

    • Presence of vascular risk factors:

      • HDL-C < 1.0 mmol/L in men, < 1.3 mmol/L in women

      • TG ≥ 1.7 mmol/L

      • Hypertension

      • Overweight

      • Abdominal obesity

      • Smoking

    • Presence of associated diseases:

      • History of pancreatitis

      • Polycystic ovary syndrome

      • Acanthosis nigricans

      • Hyperuricemia or gout

      • Nonalcoholic steatohepatitis

      • Psychiatric disorders (bipolar disorder, depression, schizophrenia)

      • HIV infection

      • Obstructive sleep apnea

      • Cystic fibrosis

    • Use of drugs associated with diabetes:

      • Glucocorticoids

      • Atypical antipsychotics

      • Statins

      • Highly active antiretroviral therapy

      • Antirejection drugs

    DC†
    Testing with 2hPG in a 75 g OGTT may be considered in individuals with FPG 6.1–6.9 mmol/L and/or A1C 6.0%–6.4% in order to identify individuals with lGT or diabetes.DC24
    Use of standardized measurement techniques and validated equipment for all methods (AOBP, non-AOBP, home BP monitoring and ambulatory BP monitoring) is recommended. Measurement using electronic (oscillometric) upper arm devices is preferred over auscultation. (Unless specified otherwise, electronic [oscillometric] measurement should be used.)HC25
    Four approaches can be used to assess BP:
    • AOBP is the preferred method of performing in-office BP measurement. When using AOBP, a displayed mean SBP ≥ 135 mm Hg or DBP ≥ 85 mm Hg is high.

    • When using non-AOBP, a mean SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg is high, and an SBP between 130 and 139 mm Hg and/or a DBP between 85 and 89 mm Hg is high-normal.

    • Using ambulatory BP monitoring, patients can be diagnosed as hypertensive if the mean awake SBP is ≥ 135 mm Hg or the DBP is ≥ 85 mm Hg, or if the mean 24-hour SBP is ≥ 130 mm Hg or the DBP is ≥ 80 mm Hg.

    • Using home BP monitoring, patients can be diagnosed as hypertensive if the mean SBP is ≥ 135 mm Hg or the DBP is ≥ 85 mm Hg. If the office BP measurement is high and the mean home BP is < 135/85 mm Hg, it is advisable to either repeat home monitoring to confirm the home BP is < 135/85 mm Hg or perform 24-hr ambulatory BP monitoring to confirm that the mean 24-hr ambulatory BP monitoring is < 130/80 mm Hg and the mean awake ambulatory BP monitoring is < 135/85 mm Hg before diagnosing white coat hypertension.

    Screening of plasma lipids for men aged ≥ 40 yr; women aged ≥ 40 yr (or postmenopausal). Consider earlier in ethnic groups at increased risk, such as South Asian or First Nations individuals.CCS26
    Screen lipids at any age for:
    • Clinical evidence of atherosclerosis

    • Abdominal aortic aneurysm

    • Diabetes mellitus

    • Arterial hypertension

    • Current cigarette smoking

    • Stigmata of dyslipidemia (arcus cornealis xanthelasma or xanthoma)

    • Family history of cardiovascular disease‡

    • Chronic kidney disease§

    • Obesity (BMI ≥ 30 kg/m2)

    • Inflammatory disease

    • HIV infection

    • Erectile dysfunction

    • Chronic obstructive pulmonary disease

    • Hypertensive diseases of pregnancy

    Tobacco use status of all patients should be updated on a regular basis and health care providers should clearly advise patients to quit smoking.HC27
    Consider informing patients of their global risk to improve the effectiveness of risk factor modification. Consider also using analogies that describe comparative risk, such as “cardiovascular age,” “vascular age,” or “heart age” to inform patients of their risk status.HC28
    Heart failure
    We recommend that patients with known or suspected heart failure should be assessed for multimorbidity, frailty, cognitive impairment, dementia and depression, all of which may affect treatment, adherence to therapy, follow-up or prognosis.HF29
    Hypertension
    Global cardiovascular risk should be assessed. Multifactorial risk assessment models can be used to:
    • Predict more accurately an individual’s global cardiovascular risk

    • Help engage individuals in conversations about health behaviour change to lower BP

    • Use antihypertensive therapy more efficiently

    In the absence of Canadian data to determine the accuracy of risk calculations, avoid using absolute levels of risk to support treatment decisions.
    HC30
    Stroke
    Persons at risk of stroke and patients who have had a stroke should be assessed for vascular disease risk factors, lifestyle management issues (diet, sodium intake, exercise, weight, alcohol intake, smoking) and use of oral contraceptives or hormone replacement therapy.
    Persons at risk of stroke should receive information and counselling about possible strategies to modify their lifestyle and risk factors.
    Referrals to appropriate specialists should be made where required. They may provide more comprehensive assessments and structured programs to manage specific risk factors.
    Stroke†
    • Note: 2hPG = post-load glucose, A1C = glycosylated hemoglobin, ACR = albumin-to-creatinine ratio, AOBP = automated office blood pressure, BMI = body mass index, BP = blood pressure, C-CHANGE = Canadian Cardiovascular Harmonized National Guideline Endeavour, CCS = Canadian Cardiovascular Society – Dyslipidemia, DBP = diastolic blood pressure, DC = Diabetes Canada (formerly Canadian Diabetes Association), eGFR = estimated glomerular filtration rate, FPG = fasting plasma glucose, GDM = gestational diabetes mellitus, HC = Hypertension Canada, HF = Canadian Cardiovascular Society – Heart Failure, HDL-C = high-density liproprotein cholesterol, IFG = impaired fasting glucose, IGT = impaired glucose tolerance, OGTT = oral glucose tolerance test, SBP = systolic blood pressure, Stroke = Heart and Stroke Foundation, TG = triglycerides.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1 for a detailed discussion of the supporting evidence. Key references are indicated in this table.)

    • ↵† Based on consensus opinion.

    • ↵‡ Men aged < 55 yr and women aged < 65 yr of age in first-degree relative.

    • ↵§ Chronic kidney disease: eGFR < 60 mL/min/1.73 m2 or ACR > 3 mg/mmol for at least 3-mo duration.

    • View popup
    Table 5:

    Diagnostic strategies: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline (key supporting reference)
    Diabetes
    Diabetes should be diagnosed by any of the following criteria:
    • FPG ≥ 7.0 mmol/L

    • A1C ≥ 6.5% (for use in adults in the absence of factors that affect the accuracy of A1C and not for use in those with suspected type 1 diabetes)

    • 2hPG in a 75 g OGTT ≥ 11.1 mmol/L

    • Random PG ≥ 11.1 mmol/L

    DC31
    Heart failure
    We recommend that BNP/NT-proBNP levels be measured to help confirm or rule out a diagnosis of heart failure in the acute or ambulatory care setting in patients in whom the cause of dyspnea is in doubt.HF32
    We recommend that patients who receive potentially cardiotoxic cancer therapy undergo evaluation of LVEF before the start of cancer treatments known to cause impairment in LV function.HF†
    Hypertension
    Routine laboratory tests that should be performed for the investigation of all patients with hypertension include the following:
    • Urinalysis

    • Blood chemistry (potassium, sodium, and creatinine)

    • Fasting blood glucose or A1C

    • Serum total cholesterol, LDL-C, HDL-C, non–HDL-C, and triglycerides; lipids may be drawn fasting or nonfasting

    • Standard 12-lead electrocardiography

    HC34
    Standardized office BP measurement should be used for follow-up. Measurement using electronic (oscillometric) upper arm devices is preferred over auscultation.HC25
    In patients with large arm circumference when standard upper arm measurement methods cannot be used, validated wrist devices (used with arm and wrist supported at heart level) may be used for blood pressure estimation.HC†
    • Note: 2hPG = post-load glucose, A1C = glycosylated hemoglobin, BNP = B-type natriuretic peptide, BP = blood pressure, C-CHANGE = Canadian Cardiovascular Harmonized National Guideline Endeavour, DC = Diabetes Canada (formerly Canadian Diabetes Association), FPG = fasting plasma glucose, FRS = Framingham Risk Score, HC = Hypertension Canada, HF = Canadian Cardiovascular Society – Heart Failure, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, LV = left ventricle, LVEF = left ventricle ejection fraction, NT-proBNP = N-terminal pro B-type natriuretic peptide, OGTT = oral glucose tolerance test, PG = plasma glucose.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1 for a detailed discussion of the supporting evidence. Key references are indicated in this table.)

    • ↵† Based on consensus opinion.

    • View popup
    Table 6:

    Risk stratification: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline (key supporting reference)
    All
    We recommend that a cardiovascular risk assessment be completed every 5 yr for men and women aged 40 to 75 yr using the modified FRS or CLEM to guide therapy to reduce major cardiovascular events. A risk assessment might also be completed whenever a patient’s expected risk status changes.CCS34
    We recommend calculating and discussing a patient’s “cardiovascular age” to improve the likelihood that patients will reach lipid targets and that poorly controlled hypertension will be treated. We recommend sharing the results of the risk assessment with the patient to support shared decision-making and improve the likelihood that patients will reach lipid targets.CCS34
    • Note: C-CHANGE = Canadian Cardiovascular Harmonized National Guidelines Endeavour, CCS = Canadian Cardiovascular Society – Dyslipidemia, CLEM = Cardiovascular Life Expectancy Model, FRS = Framingham Risk Score.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10-1503/cmaj.180194/-/DC1, for a detailed discussion of the supporting evidence. Key references are indicated in this table.)

    • View popup
    Table 7:

    Treatment targets: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline (key supporting reference)
    Diabetes
    All individuals with diabetes should follow a comprehensive, multifaceted approach to reduce CV risk, including:
    • A1C ≤ 7.0% implemented early in the course of diabetes

    • SBP of < 130 mm Hg and DBP of < 80 mm Hg

    • Additional vascular-protective medications in the majority of adult people with diabetes

    • Achievement and maintenance of healthy weight goals

    • Healthy eating

    • Regular physical activity

    • Smoking cessation

    DC35
    Therapy in most individuals with type 1 or type 2 diabetes should be targeted to achieve an A1C ≤ 7.0% to reduce the risk of microvascular and, if implemented early in the course of disease, CV complications.DC36
    In people with type 2 diabetes, an A1C ≤ 6.5% may be targeted to reduce the risk of chronic kidney disease and retinopathy if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) used, and the person’s characteristics.DC37
    A higher A1C target may be considered in people with diabetes with the goals of avoiding hypoglycemia and overtreatment related to antihyperglycemic therapy, with any of the following:
    • Functionally dependent: 7.1%–8.0%

    • History of recurrent severe hypoglycemia, especially if accompanied by hypoglycemia unawareness: 7.1%–8.5%

    • Limited life expectancy: 7.1%–8.5%

    • Frail, older age or with dementia: 7.1%–8.5%

    • End of life: A1C measurement not recommended. Avoid symptomatic hyperglycemia and any hypoglycemia.

    DC†
    An intensive healthy behaviour intervention program, combining dietary modification and increased physical activity, may be used to achieve weight loss, improve glycemic control and reduce CV risk.DC38
    Dyslipidemia
    We recommend a target LDL-C consistently < 2.0 mmol/L or > 50% reduction of LDL-C in individuals for whom treatment is begun, to decrease the risk of CVD events. Alternative target variables are apoB < 0.8 g/L or non–HDL-C < 2.6 mmol/L.CCS39
    We recommend a > 50% reduction of LDL-C for patients with LDL-C > 5.0 mmol/L in individuals for whom treatment is begun, to decrease the risk of CVD events and mortality.CCS39
    Hypertension
    For nonhypertensive individuals (to reduce the possibility of becoming hypertensive) or for hypertensive patients (to reduce their BP), prescribe the accumulation of 30–60 min of moderate intensity dynamic exercise (e.g., walking, jogging, cycling or swimming) 4–7 d/wk in addition to the routine activities of daily living.HC†
    For high-risk patients aged 50 yr or older, with SBP levels ≥ 130 mm Hg, intensive management to target an SBP of ≤ 120 mm Hg should be considered. Intensive management should be guided by AOBP measurements. Patient selection for intensive management is recommended and caution should be taken in certain high-risk groups.HC40
    Antihypertensive therapy should be prescribed for average DBP measurements of ≥ 100 mm Hg or average SBP measurements of ≥ 160 mm Hg in patients without macrovascular target organ damage or other cardiovascular risk factors. Antihypertensive therapy should be strongly considered for average DBP readings ≥ 90 mm Hg or for average SBP readings ≥ 140 mm Hg in the presence of macrovascular target organ damage or other independent cardiovascular risk factors.HC41,42
    People with diabetes mellitus should be treated to attain SBP of < 130 mm Hg and DBP of < 80 mm Hg (these target BP levels are the same as BP treatment thresholds).DC43
    Obesity
    All those considering beginning a vigorous exercise program are encouraged to consult their physician or health care team professionals.Obesity44
    • Note: A1C = glycosylated hemoglobin, AOBP = automated office blood pressure, apoB = apolipoprotein B-100, BP = blood pressure, C-CHANGE = Canadian Cardiovascular Harmonized National Guideline Endeavour, CCS = Canadian Cardiovascular Society – Dyslipidemia, CV = cardiovascular, CVD = cardiovascular disease, DBP = diastolic blood pressure, DC = Diabetes Canada (formerly Canadian Diabetes Association), HC = Hypertension Canada, HDL-C = high-density liproprotein cholesterol, HF = Canadian Cardiovascular Society – Heart Failure, LDL-C = low-density liproprotein cholesterol, Obesity = Obesity Canada, SBP = systolic blood pressure.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1 for a detailed discussion of the supporting evidence. Key references are indicated in this table.)

    • ↵† Based on consensus opinion.

    • View popup
    Table 8:

    Pharmacologic and procedural therapy for CVD risk reduction: New or updated recommendations in the 2018 C-CHANGE harmonized guideline*

    RecommendationSource guideline (key supporting reference)
    Coronary artery disease or ischemic heart disease
    In people with established CVD, low-dose ASA therapy (81 mg) should be used to prevent CV events.DC45,46
    Diabetes
    Statin therapy should be used to reduce CV risk in adults with type 1 or type 2 diabetes with any of the following features:
    • Clinical CVD

    • Age ≥ 40 yr

    • Age < 40 yr and 1 of the following:

      • Diabetes duration > 15 yr and age > 30 yr

      • Microvascular complications

      • Warrants therapy based on the presence of other CV risk factors according to the 2016 CCS Guideline for the Diagnosis and Treatment of Dyslipidemia.4

    DC47
    In adults with type 2 diabetes with clinical CVD in whom glycemic targets are not achieved with existing antihyperglycemic medication, an antihyperglycemic agent with demonstrated CV outcome benefit (empagliflozin, liraglutide, canagliflozin) should be added to reduce the risk of major CV events.
    • An SGLT2 inhibitor with demonstrated reduction in hospital admissions for heart failure may be added to reduce the risk of admission for heart failure.

    DC48–50
    ACE inhibitor or ARB, at doses that have demonstrated vascular protection, should be used to reduce CV risk in adults with type 1 or type 2 diabetes with any of the following:
    • Clinical CVD

    • Age ≥ 55 yr with an additional CV risk factor or end organ damage (albuminuria, retinopathy, left ventricular hypertrophy)

    • Microvascular complications.

    DC51
    Dyslipidemia
    We recommend management that includes statin therapy in high-risk conditions including clinical atherosclerosis, abdominal aortic aneurysm, most DM, chronic kidney disease (age > 50 yr), and those with LDL-C ≥ 5.0 mmol/L to decrease the risk of CVD events and mortality.CCS52
    For individuals not at LDL-C goal despite statin therapy as described above, a combination of statin therapy with second-line agents may be used to achieve the goal; the agent used should be selected based upon the size of the existing gap to LDL-C goal.DC†
    We recommend management that includes statin therapy for individuals at high risk (modified FRS ≥ 20%) to decrease the risk of CVD events.CCS53
    We recommend management that includes statin therapy for individuals at intermediate risk (modified FRS 10%–19%) with LDL-C ≥ 3.5 mmol/L to decrease the risk of CVD events. Statin therapy should also be considered for persons at intermediate risk with LDL-C < 3.5 mmol/L but with apoB ≥ 1.2 g/L or non–HDL-C ≥ 4.3 mmol/L, or in men aged ≥ 50 yr and women aged ≥ 60 yr with ≥ 1 CV risk factor.CCS54
    Heart failure
    We recommend that most patients with HFrEF be treated with triple therapy including an ACE inhibitor (or an ARB in those who are ACE-inhibitor intolerant), a beta blocker and an MRA unless specific contraindications exist.HF55
    We recommend loop diuretics be used to control symptoms of congestion and peripheral edema. HF† We suggest that NOACs should be the agent of choice for stroke prophylaxis in patients with HF and nonvalvular AF, and that the treatment dose be guided by patient-specific characteristics including age, weight and renal function.HF56
    We recommend that an ARNI be used in place of an ACE inhibitor or ARB, in patients with HFrEF who remain symptomatic despite treatment with appropriate doses of GDMT to decrease cardiovascular death, hospital admissions for heart failure, and symptoms.HF57
    Initial therapy should be with either monotherapy or single-pill combination.
    • Recommended monotherapy choices are:

      • A thiazide or thiazide-like diuretic, with longer-acting diuretics preferred,

      • A beta-blocker (in patients < 60 yr),

      • An ACE inhibitor (in patients who are not black),

      • An ARB, or

      • A long-acting CCB.

    • Recommended choices for single-pill combinations are those in which an ACE inhibitor is combined with a CCB, ARB with a CCB, or ACE inhibitor or ARB with a diuretic.

    • Hypokalemia should be avoided in patients treated with thiazide or thiazide-like diuretic monotherapy.

    HC58
    Alpha-blockers are not recommended as first-line agents for uncomplicated hypertension; beta-blockers are not recommended as first-line therapy for uncomplicated hypertension in patients aged ≥ 60 yr; and ACE inhibitors are not recommended as first-line therapy for uncomplicated hypertension in black patients. However, these agents may be used in patients with certain comorbid conditions or in combination therapy.HC59,60
    For patients with stable angina pectoris but without prior heart failure, MI or coronary artery bypass surgery, either a beta-blocker or a CCB can be used as initial therapy.HC61
    Stroke
    ASA (80–325 mg), combined ASA (25 mg) and extended-release dipyridamole (200 mg), or clopidogrel (75 mg) are all appropriate options; selection should depend on the clinical circumstances.Stroke62
    Patients with transient ischemic attack or ischemic stroke and nonvalvular AF should receive oral anticoagulation. In most patients requiring anticoagulants for AF, direct non–vitamin K oral anticoagulants should be prescribed in preference over warfarin.
    When selecting choice of oral anticoagulants, patient-specific criteria should be considered.
    Stroke63
    • Note: ACE = angiotensin-converting enzyme, AF = atrial fibrillation, apoB = apolipoprotein B-100, ARB = angiotensin-receptor blocker, ARNI = angiotensin receptor-neprilysin inhibitor, ASA = acetylsalicylic acid, CCB = calcium channel blocker, CCS = Canadian Cardiovascular Society – Dyslipidemia, CV = cardiovascular, CVD = cardiovascular disease, DC = Diabetes Canada (formerly Canadian Diabetes Association), DM = diabetes mellitus, FRS = Framingham Risk Score, HC = Hypertension Canada, HDL-C = high-density liproprotein cholesterol, HF = Canadian Cardiovascular Society – Heart Failure, HFrEF = heart failure with reduced ejection fraction, GDMT = guideline-directed medical therapy, LDL-C = low-density liproprotein cholesterol, MI = myocardial infarction, MRA = mineralocorticoid receptor antagonist, NOAC = new oral anticoagulant, SGLT = sodium–glucose cotransporter 2, Stroke = Heart and Stroke Foundation.

    • ↵* All recommendations are considered strong recommendations (Box 1); the quality of evidence supporting each recommendation varies (see Appendix 1 for a detailed discussion of the supporting evidence. Key references are indicated in this table.)

    • ↵† Based on consensus opinion.

    • View popup
    Table 9:

    National and international guidelines for the management of cardiovascular disease

    OrganizationRecommendations
    Canadian Task Force on Preventive Health Care98Recommend measuring height and weight and calculating BMI at appropriate primary care visits.
    American College of Cardiology/American Heart Association Hypertension guideline67Lowered the definition of hypertension to 130/80 mm Hg. Target blood pressure for all groups is now < 130/80 mm Hg.
    European Society of Hypertension/European Society of Cardiology67Base diagnosis of hypertension on out-of-office BP measures ambulatory BPM and home BPM if possible, or repeated office measures. Treatment threshold for very high CV risk now 130/85 mm Hg. BP treatment recommended for BP 140/90 mm Hg and higher in low-risk patients if no response to lifestyle intervention. Target BP < 140/90 mm Hg in all patients, < 120 mm Hg systolic if younger than 65 years, target systolic 130–139 mm Hg if 65 years or older.102
    American Diabetes Association and European Association of the Study of Diabetes99Recommend in addition to metformin, adding the newer antihyperglycemic agents, including DPP4 inhibitor, SGLT2 inhibitor and GLP-1 RA, and all groups recommend an A1c < 7.0 for most patients.
    American College of Cardiology/American Heart Association Lipid guideline100Did not recommend a specific target but did advocate more intensive therapy or combination for those who did achieve a good response to statins (i.e., > 50% reduction).
    European Society of Cardiology101Treat-to-target approach for lipid management, targeting an LDL-C < 1.8 mmol/L for very high-risk patients.
    • Note: A1C = glycosylated hemoglobin, BMI = body mass index, BP = blood pressure, BPM = blood pressure monitoring, CV = cardiovascular, DPP4 = dipeptidyl peptidase-4, GLP-1 RA = glucagon-like peptide-1 receptor agonists, LDL-C = low-density liproprotein cholesterol, SGLT2 = sodium–glucose cotransporter 2.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 190 (40)
CMAJ
Vol. 190, Issue 40
9 Oct 2018
  • Table of Contents
  • Index by author

Podcast

Subscribe to podcast
Download MP3

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update
Sheldon W. Tobe, James A. Stone, Todd Anderson, Simon Bacon, Alice Y.Y. Cheng, Stella S. Daskalopoulou, Justin A. Ezekowitz, Jean C. Gregoire, Gord Gubitz, Rahul Jain, Karim Keshavjee, Patty Lindsay, Mary L’Abbe, David C.W. Lau, Lawrence A. Leiter, Eileen O’Meara, Glen J. Pearson, Doreen M. Rabi, Diana Sherifali, Peter Selby, Jack V. Tu, Sean Wharton, Kimberly M. Walker, Diane Hua-Stewart, Peter P. Liu
CMAJ Oct 2018, 190 (40) E1192-E1206; DOI: 10.1503/cmaj.180194

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update
Sheldon W. Tobe, James A. Stone, Todd Anderson, Simon Bacon, Alice Y.Y. Cheng, Stella S. Daskalopoulou, Justin A. Ezekowitz, Jean C. Gregoire, Gord Gubitz, Rahul Jain, Karim Keshavjee, Patty Lindsay, Mary L’Abbe, David C.W. Lau, Lawrence A. Leiter, Eileen O’Meara, Glen J. Pearson, Doreen M. Rabi, Diana Sherifali, Peter Selby, Jack V. Tu, Sean Wharton, Kimberly M. Walker, Diane Hua-Stewart, Peter P. Liu
CMAJ Oct 2018, 190 (40) E1192-E1206; DOI: 10.1503/cmaj.180194
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Scope
    • Methods
    • Recommendations
    • Implementation
    • Other guidelines
    • Gaps in knowledge
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Feasibility of identifying and describing the burden of early-onset metabolic syndrome in primary care electronic medical record data: a cross-sectional analysis
  • Google Scholar

More in this TOC Section

  • Recommendations for equitable COVID-19 pandemic recovery in Canada
  • Recommendation on screening for chlamydia and gonorrhea in primary care for individuals not known to be at high risk
  • Key populations for early COVID-19 immunization: preliminary guidance for policy
Show more Guideline

Similar Articles

Collections

  • Sections
    • Guidelines

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire